Germany’s chemical and pharmaceutical industry gone through a fresh setback in the third quarter of 2026, with manufacturing, orders and sales dropping as temporary gains from earlier in the year fizzled out and increasing cost pressures broadened the sector’s woes.
The German Chemical Industry Association (VCI), in its latest quarterly report, stated the industry had lost momentum after a brief upturn in the spring, when precautionary orders by the Middle East conflict temporarily increased demand.
That support has now largely disappeared, exposing the underlying weakness of the industry. Falling order intake, dropping manufacturing and weaker sales compared with the previous quarter point to an increasingly tough business environment.
The sector also faced fresh disruptions during the July-September period. Exceptionally low water levels hit logistics, while key customers, specially in the automotive industry, cut manufacturing. Weak industrial activity throughout Germany and Europe similarly dampened demand for chemical products.
The pharmaceutical business, meanwhile, stayed volatile amid vast uncertainty in the US market.
But surging energy and raw material prices have emerged as any other major threat, increasing pressure on producers already grappling with weak demand and underused manufacturing capacity.
VCI Managing Director Wolfgang Große Entrup brought a blunt assessment of the situation, warning that the spring recovery had already run out of steam.
“The spring upturn has already fizzled out. Mnufacturing, orders, and sales in the German chemical industry are dropping. Now, gas and electricity prices are exploding. Policymakers must handle energy costs every rapidly. Meanwhile, Brussels is tightening the following cost screw with the ETS reform, putting the cart before the horse. Forcing investments affordable inexperienced green electricity, hydrogen, and networks are available – that’s not how transformation works. That’s how deindustrialization works.”
Manufacturing plunges as energy costs soar
The latest figures underline the industry’s deteriorating performance.
Seasonally adjusted chemical and pharmaceutical manufacturing fell by 4.0% in the third zone as compared with the previous quarter, leaving output 3.5% below the level recorded a year earlier.
Capacity utilisation edged up to 76.6% however stayed considerably beneath its long-term average. The VCI said the improvement was expected driven primarily by plant closures and capacity reductions instead of a meaningful growth in manufacturing.
Sales also weakened. Seasonally adjusted industry revenue decline 2.7% to €53 billion during the quarter. Although sales were 5.8% higher than a year earlier, the increase was totally attributable to price movements. In real terms, revenue stayed beneath the previous year’s level.
Manufacturers prices increased by 1.1% quarter-on-quarter and were 7.1% higher than a year earlier.
Energy costs scale up even more sharply. Gas prices increased by almost 40% compared with the previous quarter, at the same time as electricity prices climbed by more than 30%, adding to the financial strain on producers.
Recovery stays elusive
The VCI warned that the industry’s economic position in Germany stays under considerable strain, no matter stronger performances by internationally active companies in other global markets.
The association stated the sector was, at best, stabilising at a low level, with no sustained recovery recently in sight.
Its outlook for the overall year stays bleak. The VCI is maintaining its forecast of a 1.5% decline in chemical and pharmaceutical manufacturing in 2026.
Sales, however, are anticipated to surge by 3.5%, supported by considerably higher manufacturer prices. The association stressed that this projected growth could show higher prices instead of elevated manufacturing volumes.
The latest report paints a troubling picture of an industry stuck between weakening industrial demand, volatile international markets, rising energy bills and increasing regulatory costs.
For Germany’s chemical and pharmaceutical producers, the temporary spring reprieve has proved short-lived. The deeper structural pressures stay, and a meaningful turnaround is becoming increasingly difficult to see.






